Innate Pharma Sa logo

Innate Pharma Sa share price today

(IPHA)

Innate Pharma Sa share price is $1.88 & ₹161.32 as on 7 Jan 2025, 2.30 'hrs' IST

$1.88

0.01

(0.53%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Innate Pharma Sa share price in Dollar and Rupees. Guide to invest in Innate Pharma Sa stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Innate Pharma Sa, along with analyst recommendations, forecasts, and comprehensive financials.

Innate Pharma Sa share price movements

  • Today's Low: $1.86
    Today's High: $1.94

    Day's Volatility :4.1%

  • 52 Weeks Low: $1.29
    52 Weeks High: $3.51

    52 Weeks Volatility :63.26%

Innate Pharma Sa Returns

PeriodInnate Pharma SaIndex (Russel 2000)
3 Months
-12.62%
0.0%
6 Months
-13.43%
0.0%
1 Year
-36.18%
0.0%
3 Years
-58.99%
-19.8%

Innate Pharma Sa Key Statistics

in dollars & INR

Previous Close
$1.87
Open
$1.92
Today's High
$1.94
Today's Low
$1.8605
Market Capitalization
$166.4M
Today's Volume
$25.7K
52 Week High
$3.5107
52 Week Low
$1.29
Revenue TTM
$33.8M
EBITDA
$-36.0M
Earnings Per Share (EPS)
$-0.44
Profit Margin
-100.78%
Quarterly Earnings Growth YOY
-0.75%
Return On Equity TTM
-78.59%

How to invest in Innate Pharma Sa from India?

It is very easy for Indian residents to invest directly in Innate Pharma Sa from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Innate Pharma Sa stock in both Indian Rupees (INR) and US Dollars (USD). Search for Innate Pharma Sa or IPHA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Innate Pharma Sa or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Innate Pharma Sa shares which would translate to 0.456 fractional shares of Innate Pharma Sa as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Innate Pharma Sa, in just a few clicks!

Returns in Innate Pharma Sa for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Innate Pharma Sa investment value today

Current value as on today

₹67,386

Returns

₹32,614

(-32.61%)

Returns from Innate Pharma Sa Stock

₹35,836 (-35.84%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Innate Pharma Sa

160%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Innate Pharma Sa on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 160% more investors are searching Innate Pharma Sa in the last 30 days versus the previous period.

Global Institutional Holdings in Innate Pharma Sa

  • Optiver Holding B.V.

    0.11%

  • Exchange Traded Concepts, LLC

    0.10%

  • Morgan Stanley - Brokerage Accounts

    0.05%

  • Citadel Advisors Llc

    0.03%

  • UBS Group AG

    0.01%

Analyst Recommendation on Innate Pharma Sa

Buy

    70%Buy

    30%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Innate Pharma Sa(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Innate Pharma Sa

What analysts predicted

Upside of 294.26%

Current:

$1.88

Target:

$7.41

Insights on Innate Pharma Sa

  • Price Movement

    In the last 7 days, IPHA stock has moved down by -4.1%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 10.72M → 6.17M (in $), with an average decrease of 21.2% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -4.64M → -12.38M (in $), with an average decrease of 83.3% per quarter
  • IPHA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 59.7%
  • IPHA vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 114.3%
  • Price to Sales

    ForIPHA every $1 of sales, investors are willing to pay $4.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Innate Pharma Sa Financials in INR & Dollars

FY18Y/Y Change
Revenue
$90.9M
↑ 144.83%
Net Income
$3.5M
↓ 106.3%
Net Profit Margin
3.82%
↑ 152.1%
FY19Y/Y Change
Revenue
$76.6M
↓ 13.67%
Net Income
$-23.3M
↓ 787.6%
Net Profit Margin
-30.4%
↓ 34.22%
FY20Y/Y Change
Revenue
$69.1M
↓ 17.6%
Net Income
$-86.1M
↑ 237.45%
Net Profit Margin
-124.48%
↓ 94.08%
FY21Y/Y Change
Revenue
$13.7M
↓ 78.69%
Net Income
$-66.9M
↓ 16.41%
Net Profit Margin
-488.24%
↓ 363.76%
FY22Y/Y Change
Revenue
$52.5M
↑ 309.83%
Net Income
$-104.9M
↑ 67.58%
Net Profit Margin
-199.65%
↑ 288.59%
FY23Y/Y Change
Revenue
$56.6M
↑ 4.56%
Net Income
$-8.3M
↓ 92.36%
Net Profit Margin
-14.59%
↑ 185.06%
Q1 FY23Q/Q Change
Revenue
$8.9M
↓ 58.66%
Net Income
$-68.9M
↓ 7597.79%
Net Profit Margin
-775.14%
↓ 779.41%
Q2 FY23Q/Q Change
Revenue
$11.6M
↑ 29.03%
Net Income
$-5.0M
↓ 92.79%
Net Profit Margin
-43.31%
↑ 731.83%
Q3 FY23Q/Q Change
Revenue
$10.7M
↑ 0.0%
Net Income
$-4.6M
↑ 0.0%
Net Profit Margin
-43.31%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
$10.7M
↑ 0.0%
Net Income
$-4.6M
↑ 0.0%
Net Profit Margin
-43.31%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
$6.2M
↓ 42.43%
Net Income
$-12.4M
↑ 166.62%
Net Profit Margin
-200.6%
↓ 157.29%
Q2 FY24Q/Q Change
Revenue
$6.2M
↑ 0.0%
Net Income
$-12.4M
↑ 0.0%
Net Profit Margin
-200.6%
↑ 0.0%
FY18Y/Y Change
Profit
$90.9M
↑ 144.83%
FY19Y/Y Change
Profit
$26.5M
↓ 70.19%
FY20Y/Y Change
Profit
$65.4M
↑ 125.87%
FY21Y/Y Change
Profit
$-39.4M
↓ 164.87%
FY22Y/Y Change
Profit
$-2.1M
↓ 94.2%
FY23Y/Y Change
Profit
$-4.5M
↑ 103.61%
Q1 FY23Q/Q Change
Profit
$-5.4M
↓ 215.37%
Q2 FY23Q/Q Change
Profit
$-1.7M
↓ 69.02%
Q3 FY23Q/Q Change
Profit
$-1.6M
↑ 0.0%
Q4 FY23Q/Q Change
Profit
$-1.6M
↑ 0.0%
Q1 FY24Q/Q Change
Profit
$-8.4M
↑ 435.22%
Q2 FY24Q/Q Change
Profit
$-8.4M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
$-37.0M
↓ 32.31%
Investing Cash Flow
$27.6M
↓ 182.41%
Financing Cash Flow
$69.6M
↑ 6590.93%
FY19Y/Y Change
Operating Cash Flow
$38.8M
↓ 207.36%
Investing Cash Flow
$-69.0M
↓ 355.86%
Financing Cash Flow
$86.4M
↑ 27.02%
FY20Y/Y Change
Operating Cash Flow
$-63.0M
↓ 248.34%
Investing Cash Flow
$-16.3M
↓ 78.48%
Financing Cash Flow
$-1.4M
↓ 101.46%
FY21Y/Y Change
Operating Cash Flow
$-66.1M
↑ 12.84%
Investing Cash Flow
$-1.0M
↓ 93.14%
Financing Cash Flow
$30.3M
↓ 2460.74%
FY22Y/Y Change
Operating Cash Flow
$-20.3M
↓ 67.23%
Investing Cash Flow
$2.0M
↓ 304.69%
Financing Cash Flow
$-1.9M
↓ 106.82%
Q1 FY23Q/Q Change
Operating Cash Flow
$-21.6M
↑ 252.43%
Investing Cash Flow
$-131.6K
↓ 110.83%
Financing Cash Flow
$-1.1M
↑ 70.47%
Q2 FY23Q/Q Change
Operating Cash Flow
$-11.4M
↓ 47.8%
Investing Cash Flow
$-133.4K
↑ 0.0%
Financing Cash Flow
$-390.5K
↓ 66.1%

Innate Pharma Sa Technicals Summary

Sell

Neutral

Buy

Innate Pharma Sa is currently in a neutral trading position according to technical analysis indicators.

Innate Pharma Sa Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Innate Pharma Sa
-1.58%
-13.43%
-36.18%
-58.99%
-72.7%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Innate Pharma Sa
NA
NA
NA
0.0
-0.79
-0.14
NA
0.36
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Innate Pharma Sa
Buy
$166.4M
-72.7%
NA
-100.78%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Innate Pharma Sa

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma
Organization
Innate Pharma Sa
Employees
168
CEO
Mr. Yannis Morel Ph.D.
Industry
Health Technology

Management People of Innate Pharma Sa

NameTitle
Mr. Yannis Morel Ph.D.
Executive VP, COO & Member of Executive Board
Mr. Jonathan E. Dickinson
Chairman of the Executive Board & CEO
Dr. François Romagné Ph.D.
Founder
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.
Founder, Senior VP & Chief Scientific Officer
Dr. Marc Bonneville Ph.D.
Founder
Mr. Jean Jacques Fournié Ph.D.
Founder
Mr. Alessandro Moretta M.D., Ph.D.
Founder
Mr. Frederic Lombard M.B.A.
Senior VP & CFO
Dr. Sonia Quaratino M.D., Ph.D.
Executive VP, Chief Medical Officer & Member of Executive Board
Mr. Arvind Sood
Executive VP, President of US Operations & Member of Executive Board

Important FAQs about investing in Innate Pharma Sa from India :

What is Innate Pharma Sa share price today?

Innate Pharma Sa share price today stands at $1.88, Open: $1.92 ; Previous Close: $1.87 ; High: $1.94 ; Low: $1.86 ; 52 Week High: $3.51 ; 52 Week Low: $1.29. The stock opens at $1.92, after a previous close of $1.87. The stock reached a daily high of $1.94 and a low of $1.86, with a 52-week high of $3.51 and a 52-week low of $1.29.

Can Indians buy Innate Pharma Sa shares?

Yes, Indians can invest in the Innate Pharma Sa (IPHA) from India.

With INDmoney, you can buy Innate Pharma Sa at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Innate Pharma Sa at zero transaction cost.

How can I buy Innate Pharma Sa shares from India?

It is very easy to buy Innate Pharma Sa from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Innate Pharma Sa be purchased?

Yes, you can buy fractional shares of Innate Pharma Sa with INDmoney app.

What are the documents required to start investing in Innate Pharma Sa stocks?

To start investing in Innate Pharma Sa, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Innate Pharma Sa

Today’s highest price of Innate Pharma Sa (IPHA) is $1.94.

Today’s lowest price of Innate Pharma Sa (IPHA) is $1.86.

What is today's market capitalisation of Innate Pharma Sa

Today's market capitalisation of Innate Pharma Sa IPHA is 166.4M

What is the 52 Week High and Low Range of Innate Pharma Sa

  • 52 Week High

    $3.51

  • 52 Week Low

    $1.29

What are the historical returns of Innate Pharma Sa?

  • 1 Month Returns

    -1.58%

  • 3 Months Returns

    -13.43%

  • 1 Year Returns

    -36.18%

  • 5 Years Returns

    -72.7%

Who is the Chief Executive Officer (CEO) of Innate Pharma Sa

Mr. Yannis Morel Ph.D. is the current Chief Executive Officer (CEO) of Innate Pharma Sa.